| Vol. 10.02 – 21 January, 2021 |
| |
|
|
| Using tumor expression data and non-negative matrix factorization, scientists identified four small cell lung cancer (SCLC) subtypes defined largely by differential expression of transcription factors ASCL1, NEUROD1, and POU2F3 or low expression of all three transcription factor signatures accompanied by an Inflamed gene signature. [Cancer Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that secretoglobin 3A2 exhibited marked anti-cancer activity against 5 out of 11 of human NSCLC cell lines in mouse xenographs, while no effect was observed in 6 of 6 small cell lung cancer cell lines examined. [Cell Death Discovery] |
|
|
|
| Up-regulation of miR-558 alleviated cigarette smoke extract (CSE)-induced damage on HBE cells. The alleviative effect of miR-558 mimic on CSE-induced damage was suppressed by miR-558/TNF receptor superfamily member 1A (TNFRSF1A) overexpression. [Immunological Investigations] |
| |
|
|
| Through an RNAi screen performed on genes involved in chromosomal instability and overexpressed in human lung adenocarcinoma samples, scientists identified the cytoskeleton-associated protein 2-like as a potential oncogene that promotes lung cancer proliferation and growth in vitro and in vivo. [Cancer Research] |
|
|
|
| Researchers report that lncRNA linc00665 was significantly upregulated in NSCLC tissues compared with adjacent normal tissues. Linc00665 affected the sensitivity of NSCLC cells to the chemotherapy drug cisplatin, making it a potential target for the treatment of NSCLC. [Molecular Therapy-Nucleic Acids] |
|
|
|
| By generating stable human lung cancer stem cell (CSC) cell lines with the wild-type TP53, as well as cell lines in which TP53 was deleted, the authors showed that autophagy augmented the stemness of lung CSCs by degrading ubiquitinated p53. [Cell Death & Disease] |
|
|
|
| Scientists report that eukaryotic protein translation elongation factor 1α2 (EEF1A2) mediated the epithelial–mesenchymal transformation, to promote the metastasis of lung adenocarcinoma cells in vitro and in vivo. [British Journal of Cancer] |
|
|
|
| CP50-liposomes (LSs) and CP20-LSs displayed significantly enhanced cellular uptake in A549 cells in vitro as well as superior tumor accumulation in vivo compared with non-chitosan oligosaccharide modified liposomes. [Acta Pharmacologica Sinica] |
|
|
|
| GAS6-AS2 was identified, and its roles as well as mechanisms in regulating proliferation of NSCLC cells were investigated. [Cell Cycle] |
|
|
|
|
| Few treatments are available for KRAS mutant NSCLC patients, and several approaches are being tested in clinicals trials to fill this void. The authors review promising therapeutics tested for KRAS mutant NSCLC. [Cell Reports Medicine] |
|
|
|
|
| Lixte Biotechnology Holdings, Inc. announced an agreement on a Phase Ib clinical trial with City of Hope. The trial will assess the combination of Lixte’s first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease SCLC. [Lixte Biotechnology Holdings, Inc. (GlobeNewswire, Inc.)] |
|
|
|
| Genentech announced that the FDA has accepted the company’s supplemental New Drug Application and granted Priority Review for Esbriet® for the treatment of unclassifiable interstitial lung disease. [Genentech] |
|
|
|
|
| February 3 – 5, 2021 Virtual |
|
|
|
|
|
| H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| University of California, San Francisco – San Francisco, California, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| The University of Tennessee Health Science Center – Memphis, Tennessee, United States |
|
|
|
|